Connect Biopharma Holdings Ltd (NASDAQ: CNTB) shares rose 8% after announcing the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study for rademikibart. The company expects to report topline data from this study in early September 2026, followed by results from its Seabreeze STAT COPD study, with plans to discuss Phase 3 development with the FDA later this year. Connect Biopharma maintains a strong balance sheet with cash into the second half of 2027, focusing on inflammatory disease treatments.

Boston Scientific Corp. failed to convince the Federal Circuit to block the launch of Stryker Corp.'s OptaBlate BVN product, a surgical device used to treat chronic lower back pain. Boston Scientific had filed a lawsuit in July 2025 and sought an injunction, arguing that Stryker's device would lead to infringement of its US Patent No. 12,303,166.

Entergy Corp. (ETR) is attracting institutional investor interest and maintains a "Moderate Buy" consensus rating from Wall Street analysts, with a price target near $120. Recent SEC filings show hedge funds adjusting positions, reflecting the stock's defensive utility role. Entergy operates as a regulated electric utility in the US Gulf South, known for its stable earnings and infrastructure play.

Electronic Arts Inc. (EA) options trading volume reached 6,854 contracts by Wednesday at 11:21 a.m. New York time, according to Bloomberg data. Put options accounted for 4,921 contracts, while call options comprised 1,933 contracts. The August 21, 2026 $170 put was the most traded position with 2,245 contracts.

Electronics company Celestica has renewed its lease in Richardson, Texas, and will expand its operations to nearly 1 million square feet in the Innovation Quarter. This expansion includes occupying an additional 343,000 square feet currently under construction, reaffirming their presence in the city until 2036 and creating 2,300 new jobs.

While new electric vehicle sales saw a decline, used EV sales surged by 24.7% year-over-year, driven by affordability and high gas prices. Tesla leads used EV sales, followed by Hyundai, Chevrolet, Ford, and BMW. Despite a rise in average prices for used EVs, sales are expected to be bolstered by an influx of off-lease vehicles in the coming months.

FMC Corporation and Corteva have formed a co-exclusive supply and licensing agreement to expand the availability of FMC's rimisoxafen herbicide technology across corn and soybean markets in North and South America. This partnership aims to provide farmers with a new dual-action solution against resistant broadleaf weeds, strengthening both companies' crop protection portfolios. The first commercial sales of rimisoxafen-based products are anticipated by the end of the decade, pending regulatory approvals.

NextEra Energy has agreed to pay $150 million to settle a shareholder lawsuit alleging the company lied about its involvement in political interference schemes in Florida. This settlement comes about a month after NextEra announced a $67 billion merger with Dominion Energy, a deal likely to face scrutiny from Virginia utility regulators due to the past political misconduct allegations. The payout will be covered by insurance and addresses accusations such as funding "ghost" candidates and spying on a reporter.

Chegg, Inc. (CHGG) shareholders approved a potential reverse stock split at its 2026 Annual Meeting, allowing the board to implement a ratio between 1-for-4 and 1-for-15 at their discretion. This decision, along with the election of directors, approval of executive compensation, and ratification of auditors, could significantly impact the company's capital structure and share value. Investors are advised to monitor future announcements regarding the split, as it is considered the most price-sensitive outcome of the meeting.

CRISPR Therapeutics (CRSP) recently filed a US$969.16 million ESOP-related shelf registration and amended its articles of association, prompting investors to re-evaluate the company's long-term risk-reward profile. While these moves reinforce equity-based compensation and balance sheet flexibility, the core investment narrative still hinges on clinical, regulatory, and commercialization progress of its gene-editing platforms. The potential for future dilution from the large equity overhang is a key concern, especially given the wide range of fair value estimates from the Simply Wall St Community.